Free Trial
→ Elon just did WHAT!? (From Brownstone Research) (Ad) Buy BCRX Stock  Free BCRX Stock Alerts

BioCryst Pharmaceuticals (BCRX) Financials

BioCryst Pharmaceuticals logo
$10.59 +0.20 (+1.92%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$10.56 -0.04 (-0.33%)
As of 05/23/2025 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for BioCryst Pharmaceuticals

Annual Income Statements for BioCryst Pharmaceuticals

This table shows BioCryst Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Net Income / (Loss) Attributable to Common Shareholders		 -89 -225 -247 -184 -183 -109 -101 -66 -55 -43 -45
Consolidated Net Income / (Loss)		 -89 -227 -247 -184 -183 -109 -101 -66 -55 -43 -45
Net Income / (Loss) Continuing Operations		 -89 -227 -247 -184 -183 -109 -101 -66 -55 -43 -45
Total Pre-Tax Income 		-87 -226 -244 -182 -183 -109 -101 -66 -55 -43 -45
Total Operating Income		 -2.54 -104 -148 -178 -175 -99 -94 -57 -49 -39 -46
Total Gross Profit		 438 327 264 150 16 45 21 24 24 47 14
Total Revenue		 451 331 271 157 18 49 21 25 26 48 14
Operating Revenue		 451 331 271 157 18 49 21 25 26 48 14
Total Cost of Revenue		 12 4.48 6.41 7.23 1.55 3.73 0.00 1.14 2.30 1.37 0.00
Operating Cost of Revenue		 12 4.48 6.41 7.23 1.55 3.73 0.00 1.14 2.30 1.37 0.00
Total Operating Expenses		 441 431 413 328 191 145 115 81 73 86 59
Selling, General & Admin Expense		 266 214 159 119 68 37 30 14 11 13 7.46
Research & Development Expense		 175 217 253 209 123 107 85 67 61 73 52
Other Operating Expenses / (Income)		 0.22 0.18 0.19 0.04 0.13 0.38 0.47 0.56 0.40 0.53 0.12
Total Other Income / (Expense), net		 -84 -123 -96 -4.09 -8.06 -9.44 -7.03 -8.37 -6.54 -3.58 0.58
Interest Expense		 99 137 99 3.46 7.09 9.96 6.92 8.57 6.49 5.20 5.00
Interest & Investment Income		 14 15 3.14 -0.63 -0.97 0.52 - 0.19 -0.05 1.63 5.58
Income Tax Expense		 1.93 0.31 2.73 2.25 0.00 0.00 - - - - -
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 0.78 -0.18 -0.89 -0.17 0.04 -0.34 - 0.23 -0.19 0.08 0.13
Basic Earnings per Share		 ($0.43) ($1.18) ($1.33) ($1.03) ($1.09) ($940.00) ($0.98) ($0.78) ($0.75) ($0.59) ($0.68)
Weighted Average Basic Shares Outstanding		 206.70M 192.20M 185.91M 179.12M 167.27M 154.19M 103.40M 84.60M 73.30M 73M 66.77M
Diluted Earnings per Share		 ($0.43) ($1.18) ($1.33) ($1.03) ($1.09) ($940.00) ($0.98) ($0.78) ($0.75) ($0.59) ($0.68)
Weighted Average Diluted Shares Outstanding		 206.70M 192.20M 185.91M 179.12M 167.27M 115.60M 103.19M 84.45M 73.70M 72.90M 66.77M
Weighted Average Basic & Diluted Shares Outstanding		 208.96M 206.15M 188.45M 184.66M 177.18M 154.19M 103.40M 84.60M 73.30M 73M 66.77M

Quarterly Income Statements for BioCryst Pharmaceuticals

This table shows BioCryst Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 0.03 -28 -12 -13 -36 -61 -36 -75 -53 -71 -43
Consolidated Net Income / (Loss)		 0.03 -27 -14 -13 -35 -62 -36 -75 -53 -72 -43
Net Income / (Loss) Continuing Operations		 0.03 -27 -14 -13 -35 -62 -36 -75 -53 -72 -43
Total Pre-Tax Income 		0.76 -26 -13 -13 -35 -63 -36 -75 -53 -71 -41
Total Operating Income		 21 -4.51 7.69 8.76 -14 -43 -12 -21 -28 -46 -17
Total Gross Profit		 141 125 114 108 91 92 86 82 68 77 72
Total Revenue		 146 132 117 109 93 93 87 82 69 80 76
Operating Revenue		 146 132 117 109 93 93 87 82 69 80 76
Total Cost of Revenue		 4.57 6.09 3.21 1.70 1.27 1.56 1.10 0.89 0.93 2.38 3.54
Operating Cost of Revenue		 4.57 6.09 3.21 1.70 1.27 1.56 1.10 0.89 0.93 2.38 3.54
Total Operating Expenses		 120 130 106 99 106 135 98 102 96 123 90
Selling, General & Admin Expense		 82 80 65 61 59 64 51 51 48 50 37
Research & Development Expense		 37 49 41 38 46 70 47 51 48 73 53
Total Other Income / (Expense), net		 -20 -21 -21 -21 -21 -20 -24 -54 -24 -25 -24
Interest Expense		 23 24 25 25 25 25 27 58 27 26 25
Interest & Investment Income		 3.02 2.97 3.69 3.47 3.98 4.09 3.45 4.05 3.15 1.30 1.22
Other Income / (Expense), net		 0.00 - - - - - - - - - -
Income Tax Expense		 0.73 0.80 0.59 0.17 0.37 -1.43 0.33 0.74 0.67 0.08 1.52
Basic Earnings per Share		 $0.00 ($0.13) ($0.07) ($0.06) ($0.17) ($0.31) ($0.19) ($0.40) ($0.28) ($0.38) ($0.23)
Weighted Average Basic Shares Outstanding		 208.88M 206.70M 206.91M 206.43M 206.06M 192.20M 189.64M 189.12M 188.51M 185.91M 186.18M
Diluted Earnings per Share		 $0.00 ($0.13) ($0.07) ($0.06) ($0.17) ($0.31) ($0.19) ($0.40) ($0.28) ($0.38) ($0.23)
Weighted Average Diluted Shares Outstanding		 215.26M 206.70M 206.91M 206.43M 206.06M 192.20M 189.64M 189.12M 188.51M 185.91M 186.18M
Weighted Average Basic & Diluted Shares Outstanding		 209.25M 208.96M 207.13M 206.89M 206.38M 206.15M 204.81M 189.49M 188.93M 188.45M 186.42M

Annual Cash Flow Statements for BioCryst Pharmaceuticals

This table details how cash moves in and out of BioCryst Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Net Change in Cash & Equivalents		 -6.12 -194 -201 233 159 87 -25 30 -6.86 -26 33
Net Cash From Operating Activities		 -52 -95 -162 -142 -135 -90 -93 -41 -53 -13 -39
Net Cash From Continuing Operating Activities		 -52 -95 -162 -142 -135 -90 -93 -41 -53 -13 -39
Net Income / (Loss) Continuing Operations		 -89 -227 -247 -184 -183 -109 -101 -66 -55 -43 -45
Consolidated Net Income / (Loss)		 -89 -227 -247 -184 -183 -109 -101 -66 -55 -43 -45
Depreciation Expense		 1.25 1.66 1.44 0.78 0.75 0.72 0.77 0.70 0.48 0.18 0.18
Amortization Expense		 56 76 97 54 3.45 1.40 1.00 1.03 1.08 1.01 0.59
Non-Cash Adjustments To Reconcile Net Income		 67 87 46 -21 16 18 9.40 13 8.50 9.71 10
Changes in Operating Assets and Liabilities, net		 -87 -32 -59 8.12 28 -0.53 -2.48 10 -8.36 19 -4.33
Net Cash From Investing Activities		 53 -131 -128 16 -6.86 78 4.77 -65 23 -18 -40
Net Cash From Continuing Investing Activities		 53 -131 -128 16 -6.86 78 4.77 -65 23 -18 -40
Purchase of Property, Plant & Equipment		 -1.12 -2.17 -1.35 -2.39 -0.51 -0.34 -0.37 -0.33 -5.28 -5.12 -0.11
Purchase of Investments		 -267 -514 -244 -10 -50 -3.02 -63 -108 -14 -54 -74
Sale and/or Maturity of Investments		 320 385 117 28 43 81 68 43 43 42 34
Net Cash From Financing Activities		 -5.76 32 88 360 301 99 63 136 23 5.48 112
Net Cash From Continuing Financing Activities		 -5.76 32 88 360 301 99 63 136 23 5.48 112
Repayment of Debt		 0.00 -273 0.00 0.00 -52 0.00 -4.03 0.00 0.00 0.00 0.00
Issuance of Debt		 0.00 300 73 0.00 120 19 10 0.00 23 - -
Issuance of Common Equity		 3.44 8.34 15 66 108 78 53 134 0.00 0.00 107
Other Financing Activities, net		 -9.21 -3.00 0.19 294 125 1.24 2.78 1.70 0.65 5.48 5.31
Effect of Exchange Rate Changes		 -0.94 0.36 0.57 0.07 - 0.00 - - - - -
Cash Interest Paid		 30 22 0.00 0.90 - - - - - - -
Cash Income Taxes Paid		 1.60 1.43 3.54 0.12 - - - - - - -

Quarterly Cash Flow Statements for BioCryst Pharmaceuticals

This table details how cash moves in and out of BioCryst Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 0.56 7.26 19 -5.93 -26 -40 4.70 -8.81 -150 58 -26
Net Cash From Operating Activities		 -28 -5.21 8.25 -1.37 -54 -8.92 -20 -19 -48 -24 -32
Net Cash From Continuing Operating Activities		 -28 -5.21 8.25 -1.37 -54 -8.92 -20 -19 -48 -24 -32
Net Income / (Loss) Continuing Operations		 0.03 -27 -14 -13 -35 -62 -36 -75 -53 -72 -43
Consolidated Net Income / (Loss)		 0.03 -27 -14 -13 -35 -62 -36 -75 -53 -72 -43
Depreciation Expense		 0.33 0.31 0.31 0.32 0.31 0.42 0.42 0.41 0.41 0.40 0.39
Amortization Expense		 13 11 12 16 16 16 20 21 19 43 18
Non-Cash Adjustments To Reconcile Net Income		 22 21 19 13 14 18 12 42 14 16 9.95
Changes in Operating Assets and Liabilities, net		 -62 -11 -9.13 -18 -49 18 -16 -6.64 -28 -12 -18
Net Cash From Investing Activities		 27 18 8.49 -2.45 29 -28 23 -19 -107 77 -70
Net Cash From Continuing Investing Activities		 27 18 8.49 -2.45 29 -28 23 -19 -107 77 -70
Purchase of Property, Plant & Equipment		 -0.14 -0.68 -0.06 -0.16 -0.24 -0.55 -0.99 -0.47 -0.16 -0.53 -0.18
Purchase of Investments		 -49 -40 -27 -112 -88 -157 -124 -85 -149 - -105
Sale and/or Maturity of Investments		 76 58 35 110 117 129 148 66 42 78 36
Net Cash From Financing Activities		 0.53 -4.02 1.27 -1.97 -1.05 -3.17 1.23 29 5.08 4.20 76
Net Cash From Continuing Financing Activities		 0.53 -4.02 1.27 -1.97 -1.05 -3.17 1.23 29 5.08 4.20 76
Issuance of Common Equity		 2.39 -0.59 2.09 0.26 1.68 0.04 1.48 1.75 5.08 - -
Other Financing Activities, net		 -1.86 -3.44 -0.81 -2.23 -2.73 -3.21 0.01 0.21 0.00 -11 3.25
Effect of Exchange Rate Changes		 0.45 -1.30 0.85 -0.14 -0.34 0.52 0.25 -0.32 -0.10 0.33 -0.01
Cash Interest Paid		 9.15 10 10 5.05 4.99 4.99 4.85 5.16 7.14 - -
Cash Income Taxes Paid		 0.00 0.38 0.36 0.68 0.19 -0.01 0.32 0.98 0.14 - -

Annual Balance Sheets for BioCryst Pharmaceuticals

This table presents BioCryst Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Total Assets		 490 517 550 588 335 175 147 178 90 122 137
Total Current Assets		 422 496 517 566 324 164 114 125 67 64 89
Cash & Equivalents		 105 111 305 504 272 114 27 50 22 29 55
Restricted Cash		 0.21 1.80 1.47 3.35 2.22 1.55 1.54 3.29 1.55 1.61 0.15
Short-Term Investments		 216 278 120 3.21 28 22 78 64 33 23 18
Accounts Receivable		 79 57 51 29 8.65 22 4.29 6.12 8.77 6.24 9.49
Inventories, net		 8.09 29 28 16 7.04 0.00 1.65 0.00 0.50 1.61 0.68
Prepaid Expenses		 14 20 13 9.99 5.53 4.42 2.40 1.38 1.44 2.67 6.17
Plant, Property, & Equipment, net		 7.78 7.91 8.62 8.71 7.11 7.35 - 9.55 9.92 5.15 0.21
Total Noncurrent Assets		 61 13 25 13 3.80 3.59 - 43 13 53 47
Long-Term Investments		 20 0.00 18 6.83 0.00 - 22 41 8.93 48 41
Other Noncurrent Operating Assets		 40 13 6.81 6.47 3.80 3.59 0.98 2.03 4.01 5.73 6.21
Total Liabilities & Shareholders' Equity		 490 517 550 588 335 175 147 178 90 122 137
Total Liabilities		 966 972 845 695 354 137 - 94 88 75 61
Total Current Liabilities		 160 150 106 104 106 92 69 75 54 62 57
Accounts Payable		 12 21 14 28 19 14 7.77 6.34 4.27 9.31 2.85
Accrued Expenses		 113 103 88 73 34 21 16 13 11 16 11
Other Current Liabilities		 35 26 2.37 1.82 1.18 1.38 - - - - -
Total Noncurrent Liabilities		 806 823 739 591 248 45 - 20 34 12 3.95
Long-Term Debt		 315 303 232 136 120 41 25 17 23 0.00 -
Other Noncurrent Operating Liabilities		 491 519 507 455 129 0.00 2.70 - - - -
Total Equity & Noncontrolling Interests		 -476 -456 -295 -107 -19 38 - 84 1.58 48 76
Total Preferred & Common Equity		 -476 -456 -295 -107 -19 38 - 84 1.58 48 76
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -476 -456 -295 -107 -19 38 - 84 1.58 48 76
Common Stock		 1,293 1,224 1,160 1,100 1,004 879 782 716 568 559 544
Retained Earnings		 -1,770 -1,681 -1,455 -1,208 -1,023 -841 -732 -632 -566 -511 -468
Accumulated Other Comprehensive Income / (Loss)		 0.92 1.34 0.03 0.18 0.00 0.04 -0.30 -0.24 -0.01 -0.21 -0.13

Quarterly Balance Sheets for BioCryst Pharmaceuticals

This table presents BioCryst Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 480 491 472 468 523 530 510 559
Total Current Assets		 410 427 363 447 502 511 491 509
Cash & Equivalents		 105 97 78 84 151 146 155 247
Restricted Cash		 0.29 0.81 1.80 1.80 1.58 1.57 1.46 1.44
Short-Term Investments		 190 233 194 252 247 264 243 180
Accounts Receivable		 93 72 69 61 54 58 49 43
Inventories, net		 6.87 7.56 4.45 30 30 27 27 27
Prepaid Expenses		 14 16 16 18 20 14 15 11
Plant, Property, & Equipment, net		 7.59 7.42 7.66 7.83 9.00 8.44 8.38 8.46
Total Noncurrent Assets		 62 57 101 13 11 10 10 41
Long-Term Investments		 21 19 64 - 0.00 3.45 3.43 34
Other Noncurrent Operating Assets		 42 37 37 13 11 6.95 7.05 6.80
Total Liabilities & Shareholders' Equity		 480 491 472 468 523 530 510 559
Total Liabilities		 932 960 948 944 934 919 838 801
Total Current Liabilities		 140 154 129 120 91 93 85 82
Accounts Payable		 10 13 7.79 12 11 14 6.25 8.62
Accrued Expenses		 93 104 90 79 77 75 75 69
Other Current Liabilities		 37 36 32 29 2.28 2.53 2.49 2.20
Total Noncurrent Liabilities		 792 806 819 824 843 825 753 720
Long-Term Debt		 315 314 314 308 298 293 233 224
Capital Lease Obligations		 2.31 - - - 9.97 5.80 5.93 5.97
Other Noncurrent Operating Liabilities		 474 492 505 516 535 526 514 490
Total Equity & Noncontrolling Interests		 -452 -469 -476 -476 -411 -389 -328 -243
Total Preferred & Common Equity		 -452 -469 -476 -476 -411 -389 -328 -243
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -452 -469 -476 -476 -411 -389 -328 -243
Common Stock		 1,317 1,272 1,253 1,240 1,208 1,194 1,179 1,141
Retained Earnings		 -1,770 -1,743 -1,729 -1,717 -1,619 -1,583 -1,508 -1,383
Accumulated Other Comprehensive Income / (Loss)		 1.13 2.29 0.56 0.77 0.80 0.69 0.59 -0.10

Annual Metrics And Ratios for BioCryst Pharmaceuticals

This table displays calculated financial ratios and metrics derived from BioCryst Pharmaceuticals' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 36.00% 22.37% 72.31% 782.38% -63.53% 136.45% -18.00% -4.43% -45.39% 254.62% -21.48%
EBITDA Growth		 306.82% 46.82% 59.38% 28.04% -75.23% -5.16% -66.26% -18.35% -22.97% 15.00% -349.00%
EBIT Growth		 97.55% 30.13% 16.48% -1.70% -75.71% -5.44% -64.30% -18.11% -23.23% 13.82% -364.10%
NOPAT Growth		 97.55% 30.13% 16.48% -1.70% -75.71% -5.56% -64.11% -18.11% -23.23% 13.82% -284.87%
Net Income Growth		 60.77% 8.33% -34.26% -0.68% -67.88% -7.55% -53.92% -19.29% -28.19% 4.80% -50.09%
EPS Growth		 63.56% 11.28% -29.13% 5.50% 99.88% -95,818.37% -25.64% -4.00% -27.12% 13.24% 0.00%
Operating Cash Flow Growth		 45.32% 41.22% -13.85% -5.22% -50.82% 3.22% -124.98% 23.01% -307.43% 65.98% -45.31%
Free Cash Flow Firm Growth		 -16.73% 57.62% -140.10% 698.80% 134.99% -15.71% -102.67% 33.97% -258.63% 63.47% -289.85%
Invested Capital Growth		 7.48% -7.15% -3.71% -224.82% -11,085.43% 83.66% 1.94% -911.33% 94.88% -582.77% 70.50%
Revenue Q/Q Growth		 9.24% 4.36% 13.58% 37.83% -66.72% 312.49% -5.32% -16.82% 19.94% -1.72% 0.00%
EBITDA Q/Q Growth		 154.10% -677.54% 38.49% 11.32% -42.04% 20.71% -8.91% -20.99% 16.30% -5.73% -483.61%
EBIT Q/Q Growth		 93.75% 3.39% 3.80% 0.13% -42.70% 20.19% -8.65% -20.26% 15.63% -5.45% -512.39%
NOPAT Q/Q Growth		 93.75% 3.39% 3.80% 0.13% -42.70% 20.19% -8.52% -20.26% 15.63% -5.45% -512.39%
Net Income Q/Q Growth		 28.22% 4.15% -27.81% 18.84% -46.32% 18.56% -8.45% -29.64% 19.82% -17.68% -16.03%
EPS Q/Q Growth		 29.51% 5.60% -26.67% -100.21% 99.92% -77,585.95% -5.38% -21.88% 19.35% -15.69% -11.48%
Operating Cash Flow Q/Q Growth		 6.65% 13.56% 5.05% 6.62% -31.14% 13.13% -17.02% -12.79% 14.38% -7.70% -32.13%
Free Cash Flow Firm Q/Q Growth		 -61.84% 24.92% -141.00% 1,088.45% 127.97% -13.38% -13.58% 3.07% 43.11% -193.83% -484.81%
Invested Capital Q/Q Growth		 0.40% -8.14% -6.60% -208.71% -855.62% 94.77% -37.46% -144.94% 77.38% 67.69% 74.50%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 97.28% 98.65% 97.63% 95.40% 91.30% 92.37% 100.00% 95.47% 91.28% 97.17% 99.99%
EBITDA Margin		 12.17% -8.00% -18.41% -78.09% -957.57% -199.32% -448.18% -221.05% -178.51% -79.27% -330.72%
Operating Margin		 -0.56% -31.29% -54.81% -113.08% -981.12% -203.66% -456.20% -227.95% -184.45% -81.74% -336.35%
EBIT Margin		 -0.56% -31.29% -54.81% -113.08% -981.12% -203.66% -456.73% -227.95% -184.45% -81.74% -336.35%
Profit (Net Income) Margin		 -19.72% -68.36% -91.25% -117.11% -1,026.35% -222.99% -490.25% -261.18% -209.25% -89.15% -332.08%
Tax Burden Percent		 102.22% 100.14% 101.12% 101.24% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 3,419.35% 218.14% 164.64% 102.30% 104.61% 109.49% 107.34% 114.58% 113.45% 109.06% 98.73%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 19.08% 60.40% 123.07% 291.59% -1,925.37% -248.94% -152.26% -154.16% -223.70% -69.75% -121.30%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -0.50% -19.44% -26.08% -38.51% -68.53% -61.75% -58.03% -42.83% -45.81% -30.43% -49.29%
Return on Assets (ROA)		 -17.65% -42.46% -43.42% -39.89% -71.69% -67.61% -62.29% -49.07% -51.97% -33.19% -48.66%
Return on Common Equity (ROCE)		 19.08% 60.40% 123.07% 291.59% -1,925.37% -248.94% -152.26% -154.16% -223.70% -69.75% -121.30%
Return on Equity Simple (ROE_SIMPLE)		 18.68% 49.73% 83.88% 172.04% 949.09% -284.68% -205.65% -78.53% -3,494.55% -90.14% -59.75%
Net Operating Profit after Tax (NOPAT)		 -1.78 -73 -104 -124 -122 -70 -66 -40 -34 -28 -32
NOPAT Margin		 -0.40% -21.91% -38.37% -79.15% -686.78% -142.56% -319.34% -159.56% -129.11% -57.22% -235.45%
Net Nonoperating Expense Percent (NNEP)		 -152.71% -102.70% -48.23% -23.26% -70.83% -80.93% -47.18% -54.13% -63.67% -21.71% -30.97%
Return On Investment Capital (ROIC_SIMPLE)		 1.11% 47.67% 165.00% - - - - - - - -
Cost of Revenue to Revenue		 2.72% 1.35% 2.37% 4.60% 8.70% 7.63% 0.00% 4.53% 8.72% 2.83% 0.01%
SG&A Expenses to Revenue		 59.05% 64.54% 58.85% 75.60% 381.37% 76.01% 142.90% 55.32% 42.70% 27.04% 54.83%
R&D to Revenue		 38.75% 65.35% 93.53% 132.85% 690.34% 219.24% 411.02% 265.87% 231.50% 150.77% 380.63%
Operating Expenses to Revenue		 97.84% 129.94% 152.44% 208.48% 1,072.42% 296.03% 556.20% 323.41% 275.73% 178.90% 436.35%
Earnings before Interest and Taxes (EBIT)		 -2.54 -104 -148 -178 -175 -99 -94 -57 -49 -39 -46
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 55 -27 -50 -123 -171 -97 -93 -56 -47 -38 -45
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 9.96 17.97 5.77 295.87 15.86 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 9.96 17.97 5.77 295.87 15.86 0.00
Price to Revenue (P/Rev)		 3.46 3.70 7.90 15.86 73.85 7.80 42.84 19.18 17.72 15.68 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 3.40 3.44 7.12 13.43 65.27 6.69 39.49 15.04 17.28 14.22 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 27.92 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 9.87 43.43 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -0.66 -0.67 -0.79 -1.27 -7.77 2.18 1.20 0.65 34.05 0.63 0.40
Long-Term Debt to Equity		 -0.66 -0.67 -0.79 -1.27 -6.22 1.17 0.52 0.23 16.15 0.05 0.00
Financial Leverage		 0.12 0.40 1.48 4.06 -8.99 -1.11 -1.13 -1.11 -1.35 -1.15 -1.14
Leverage Ratio		 -1.08 -1.42 -2.83 -7.31 26.86 3.68 2.44 3.14 4.30 2.10 2.49
Compound Leverage Factor		 -36.98 -3.10 -4.67 -7.48 28.09 4.03 2.62 3.60 4.88 2.29 2.46
Debt to Total Capital		 -195.49% -199.11% -367.81% 467.70% 114.76% 68.52% 54.54% 39.51% 97.15% 38.74% 28.40%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 22.99% 31.75% 31.12% 25.43% 51.07% 35.69% 28.40%
Long-Term Debt to Total Capital		 -195.49% -199.11% -367.81% 467.70% 91.77% 36.78% 23.43% 14.08% 46.08% 3.05% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 295.49% 299.11% 467.81% -367.70% -14.76% 31.48% 45.46% 60.49% 2.85% 61.26% 71.60%
Debt to EBITDA		 5.74 -11.44 -4.65 -1.11 -0.88 -0.86 -0.64 -0.98 -1.14 -0.79 -0.67
Net Debt to EBITDA		 -0.48 3.30 4.26 3.11 0.90 0.56 0.75 1.87 0.24 1.85 1.87
Long-Term Debt to EBITDA		 5.74 -11.44 -4.65 -1.11 -0.70 -0.46 -0.27 -0.35 -0.54 -0.06 0.00
Debt to NOPAT		 -176.88 -4.18 -2.23 -1.09 -1.22 -1.20 -0.90 -1.36 -1.58 -1.09 -0.94
Net Debt to NOPAT		 14.89 1.21 2.04 3.07 1.25 0.78 1.05 2.59 0.34 2.56 2.62
Long-Term Debt to NOPAT		 -176.88 -4.18 -2.23 -1.09 -0.98 -0.64 -0.38 -0.49 -0.75 -0.09 0.00
Altman Z-Score		 -2.54 -3.01 -1.68 -0.51 -2.94 -6.15 -3.15 -2.48 -6.97 -0.42 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.63 3.31 4.90 5.46 3.06 1.78 1.65 1.68 1.23 1.02 1.56
Quick Ratio		 2.49 2.97 4.50 5.18 2.92 1.72 1.57 1.61 1.17 0.93 1.44
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -42 -36 -86 214 27 -77 -66 -33 -49 -14 -38
Operating Cash Flow to CapEx		 -4,628.11% -4,388.42% -11,980.01% -5,960.46% -26,285.60% -26,117.78% -25,290.98% -13,019.94% -1,012.66% -256.07% -36,368.87%
Free Cash Flow to Firm to Interest Expense		 -0.43 -0.26 -0.87 61.87 3.77 -7.68 -9.55 -3.81 -7.62 -2.65 -7.55
Operating Cash Flow to Interest Expense		 -0.53 -0.69 -1.63 -41.13 -19.05 -9.00 -13.37 -4.80 -8.24 -2.52 -7.71
Operating Cash Flow Less CapEx to Interest Expense		 -0.54 -0.71 -1.65 -41.82 -19.12 -9.03 -13.42 -4.84 -9.05 -3.51 -7.73
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.89 0.62 0.48 0.34 0.07 0.30 0.13 0.19 0.25 0.37 0.15
Accounts Receivable Turnover		 6.63 6.16 6.77 8.26 1.16 3.69 3.97 3.38 3.51 6.13 2.35
Inventory Turnover		 0.67 0.16 0.30 0.63 0.00 0.00 0.00 0.00 2.18 1.19 0.00
Fixed Asset Turnover		 57.46 40.11 31.25 19.86 2.46 5.93 2.21 2.59 3.50 18.02 53.05
Accounts Payable Turnover		 0.75 0.25 0.30 0.31 0.09 0.34 0.00 0.22 0.34 0.23 0.00
Days Sales Outstanding (DSO)		 55.08 59.22 53.92 44.19 315.49 98.80 91.99 107.86 103.95 59.50 155.64
Days Inventory Outstanding (DIO)		 546.95 2,289.54 1,233.87 576.36 0.00 0.00 0.00 0.00 167.80 306.17 0.00
Days Payable Outstanding (DPO)		 483.98 1,435.60 1,200.83 1,174.45 3,850.28 1,065.66 0.00 1,694.92 1,078.63 1,621.69 1,281,697.50
Cash Conversion Cycle (CCC)		 118.04 913.16 86.95 -553.90 -3,534.79 -966.86 91.99 -1,587.06 -806.88 -1,256.02 -1,281,541.86
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -502 -543 -507 -489 -150 -1.35 -8.23 -8.39 -0.83 -16 -2.37
Invested Capital Turnover		 -0.86 -0.63 -0.54 -0.49 -0.23 -10.20 -2.48 -5.46 -3.09 -5.19 -2.61
Increase / (Decrease) in Invested Capital		 41 -36 -18 -338 -149 6.89 0.16 -7.56 15 -14 5.67
Enterprise Value (EV)		 1,531 1,139 1,928 2,110 1,163 327 815 379 455 686 0.00
Market Capitalization		 1,558 1,227 2,140 2,492 1,315 381 885 483 467 757 0.00
Book Value per Share		 ($2.30) ($2.22) ($1.58) ($0.59) ($0.11) $0.35 $0.45 $0.85 $0.02 $0.65 $1.13
Tangible Book Value per Share		 ($2.30) ($2.22) ($1.58) ($0.59) ($0.11) $0.35 $0.45 $0.85 $0.02 $0.65 $1.13
Total Capital		 -161 -152 -63 29 130 122 108 138 55 78 106
Total Debt		 315 303 232 136 150 83 59 55 54 30 30
Total Long-Term Debt		 315 303 232 136 120 45 25 20 25 2.38 0.00
Net Debt		 -27 -88 -212 -382 -153 -55 -69 -104 -11 -71 -84
Capital Expenditures (CapEx)		 1.12 2.17 1.35 2.39 0.51 0.34 0.37 0.32 5.28 5.12 0.11
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -59 -45 -15 -49 -54 -27 -27 -32 -15 -24 -11
Debt-free Net Working Capital (DFNWC)		 262 346 411 462 248 111 79 86 41 29 62
Net Working Capital (NWC)		 262 346 411 462 218 72 45 51 13 1.54 32
Net Nonoperating Expense (NNE)		 87 154 143 60 60 39 35 26 21 15 13
Net Nonoperating Obligations (NNO)		 -27 -88 -212 -382 -131 -40 -57 -92 -2.41 -64 -78
Total Depreciation and Amortization (D&A)		 57 77 99 55 4.19 2.12 1.77 1.74 1.56 1.19 0.77
Debt-free, Cash-free Net Working Capital to Revenue		 -13.20% -13.52% -5.46% -30.88% -305.64% -55.67% -132.84% -126.69% -58.16% -49.39% -79.89%
Debt-free Net Working Capital to Revenue		 58.04% 104.40% 151.75% 294.22% 1,393.14% 226.46% 380.46% 340.57% 155.09% 60.80% 455.98%
Net Working Capital to Revenue		 58.04% 104.40% 151.75% 294.22% 1,224.71% 147.46% 217.28% 200.73% 47.91% 3.19% 235.52%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.43) ($1.18) ($1.33) ($1,030.00) ($1.09) ($0.94) ($0.98) ($0.78) ($0.75) $0.00 ($0.68)
Adjusted Weighted Average Basic Shares Outstanding		 206.70M 192.20M 185.91M 184.66M 177.18M 154.19M 110.18M 98.61M 73.96M 73.58M 72.32M
Adjusted Diluted Earnings per Share		 ($0.43) ($1.18) ($1.33) ($1,030.00) ($1.09) ($0.94) ($0.98) ($0.78) ($0.75) $0.00 ($0.68)
Adjusted Weighted Average Diluted Shares Outstanding		 206.70M 192.20M 185.91M 179.12M 167.27M 115.60M 103.19M 84.45M 73.70M 73.58M 72.32M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($1,030.00) ($1.09) ($0.94) ($0.98) ($0.78) ($0.75) ($0.59) ($0.68)
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 208.96M 206.15M 188.45M 184.66M 177.18M 154.19M 110.18M 98.61M 73.96M 73.58M 66.77M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.78 -73 -104 -124 -122 -70 -66 -40 -34 -28 -32
Normalized NOPAT Margin		 -0.40% -21.91% -38.37% -79.15% -686.78% -142.56% -319.34% -159.56% -129.11% -57.22% -235.45%
Pre Tax Income Margin		 -19.29% -68.26% -90.24% -115.68% -1,026.35% -222.99% -490.25% -261.18% -209.25% -89.15% -332.08%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -0.03 -0.76 -1.50 -51.42 -24.64 -9.99 -13.62 -6.70 -7.49 -7.59 -9.16
NOPAT to Interest Expense		 -0.02 -0.53 -1.05 -36.00 -17.25 -6.99 -9.53 -4.69 -5.25 -5.31 -6.41
EBIT Less CapEx to Interest Expense		 -0.04 -0.77 -1.51 -52.11 -24.71 -10.02 -13.68 -6.74 -8.31 -8.57 -9.18
NOPAT Less CapEx to Interest Expense		 -0.03 -0.54 -1.06 -36.69 -17.32 -7.03 -9.58 -4.73 -6.06 -6.29 -6.43
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for BioCryst Pharmaceuticals

This table displays calculated financial ratios and metrics derived from BioCryst Pharmaceuticals' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 56.89% 40.83% 34.98% 32.54% 34.87% 17.42% 14.39% 25.88% 37.77% 68.68% 84.97%
EBITDA Growth		 1,548.24% 127.03% 148.32% 4,162.10% 122.63% -751.35% 1,257.40% 103.52% 70.01% 91.03% 101.99%
EBIT Growth		 246.52% 89.44% 164.52% 142.32% 49.01% 7.86% 31.67% 40.38% 43.12% 11.24% 60.87%
NOPAT Growth		 108.84% 89.44% 164.52% 142.32% 49.01% 7.86% 31.67% 40.38% 43.12% 11.24% 60.87%
Net Income Growth		 100.09% 56.59% 61.18% 83.17% 33.66% 13.71% 14.98% -27.98% 28.12% -302.39% 27.69%
EPS Growth		 100.00% 58.06% 63.16% 85.00% 39.29% 18.42% 17.39% -25.00% 30.00% -280.00% 30.30%
Operating Cash Flow Growth		 48.74% 41.55% 141.44% 92.73% -12.99% 62.61% 38.67% 32.22% 38.93% 26.53% -39.39%
Free Cash Flow Firm Growth		 -1,927.87% -785.70% -58.32% -93.33% 37.26% 144.77% -93.97% -96.98% -99.26% -104.73% 173.87%
Invested Capital Growth		 11.05% 7.48% -0.45% 1.09% -2.67% -7.15% -5.62% -4.98% -4.69% -3.71% -200.35%
Revenue Q/Q Growth		 10.64% 12.34% 7.09% 17.86% -0.69% 7.68% 5.15% 19.94% -13.54% 4.90% 15.71%
EBITDA Q/Q Growth		 383.74% -65.47% -18.64% 1,112.76% 107.93% -417.21% 1,296.45% 106.44% -198.50% -605.76% 103.62%
EBIT Q/Q Growth		 570.90% -158.61% -12.20% 160.47% 66.05% -257.94% 42.42% 27.14% 38.64% -165.47% 49.76%
NOPAT Q/Q Growth		 128.40% -158.61% -12.20% 160.47% 66.05% -257.94% 42.42% 27.14% 38.64% -165.47% 49.76%
Net Income Q/Q Growth		 100.12% -90.94% -10.72% 64.18% 42.69% -70.77% 52.01% -41.24% 25.45% -68.25% 27.76%
EPS Q/Q Growth		 100.00% -85.71% -16.67% 64.71% 45.16% -63.16% 52.50% -42.86% 26.32% -65.22% 28.13%
Operating Cash Flow Q/Q Growth		 -427.85% -163.23% 702.70% 97.45% -501.97% 55.18% -5.76% 60.40% -99.22% 26.49% -16.89%
Free Cash Flow Firm Q/Q Growth		 -25.60% -671.19% 1,111.85% -78.98% -15.04% -65.28% 94.01% 332.47% 115.37% -104.68% -3.01%
Invested Capital Q/Q Growth		 10.41% 0.40% -0.91% 1.21% 6.33% -8.14% 0.64% -2.54% 2.75% -6.60% 1.24%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 96.86% 95.37% 97.26% 98.45% 98.64% 98.33% 98.73% 98.92% 98.65% 97.00% 95.33%
EBITDA Margin		 23.52% 5.38% 17.50% 23.04% 2.24% -28.03% 9.51% 0.72% -13.35% -3.87% 0.80%
Operating Margin		 14.59% -3.43% 6.57% 8.01% -15.62% -45.68% -13.74% -25.10% -41.31% -58.22% -23.01%
EBIT Margin		 14.59% -3.43% 6.57% 8.01% -15.62% -45.68% -13.74% -25.10% -41.31% -58.22% -23.01%
Profit (Net Income) Margin		 0.02% -20.37% -11.99% -11.59% -38.14% -66.09% -41.67% -91.31% -77.54% -89.94% -56.08%
Tax Burden Percent		 4.22% 103.09% 104.36% 101.38% 101.04% 97.73% 100.92% 100.99% 101.27% 100.11% 103.71%
Interest Burden Percent		 3.57% 576.55% -174.82% -142.70% 241.68% 148.02% 300.47% 360.27% 185.33% 154.32% 235.01%
Effective Tax Rate		 95.78% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 11.52% 19.08% 28.15% 33.77% 51.86% 60.40% 72.32% 80.65% 91.88% 123.07% 99.23%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 15.49% -3.07% 5.35% 6.11% -11.36% -28.38% -8.07% -14.79% -23.07% -27.71% -13.31%
Return on Assets (ROA)		 0.02% -18.23% -9.75% -8.84% -27.73% -41.06% -24.47% -53.83% -43.30% -42.80% -32.44%
Return on Common Equity (ROCE)		 11.52% 19.08% 28.15% 33.77% 51.86% 60.40% 72.32% 80.65% 91.88% 123.07% 99.23%
Return on Equity Simple (ROE_SIMPLE)		 11.83% 0.00% 26.42% 30.68% 43.81% 0.00% 57.51% 62.44% 68.92% 0.00% 79.68%
Net Operating Profit after Tax (NOPAT)		 0.90 -3.16 5.38 6.13 -10 -30 -8.34 -14 -20 -32 -12
NOPAT Margin		 0.62% -2.40% 4.60% 5.61% -10.93% -31.98% -9.62% -17.57% -28.92% -40.75% -16.10%
Net Nonoperating Expense Percent (NNEP)		 -6.16% -41.45% -30.55% -26.67% -25.96% -21.26% -17.16% -31.61% -14.20% -13.17% -24.84%
Return On Investment Capital (ROIC_SIMPLE)		 -0.67% 1.96% - - - 19.61% - - - 51.48% -
Cost of Revenue to Revenue		 3.14% 4.63% 2.74% 1.55% 1.36% 1.67% 1.27% 1.08% 1.35% 3.00% 4.67%
SG&A Expenses to Revenue		 56.67% 61.18% 55.59% 55.99% 64.00% 68.93% 58.39% 61.82% 69.60% 63.05% 48.69%
R&D to Revenue		 25.61% 37.59% 35.09% 34.41% 50.12% 75.00% 54.04% 62.12% 70.35% 92.03% 69.55%
Operating Expenses to Revenue		 82.28% 98.79% 90.69% 90.43% 114.25% 144.02% 112.48% 124.01% 139.96% 155.22% 118.33%
Earnings before Interest and Taxes (EBIT)		 21 -4.51 7.69 8.76 -14 -43 -12 -21 -28 -46 -17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 34 7.08 20 25 2.08 -26 8.25 0.59 -9.18 -3.08 0.61
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 3.11 3.46 3.81 3.34 2.93 3.70 4.22 4.34 5.43 7.90 9.83
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 3.12 3.40 3.72 3.27 2.84 3.44 3.94 3.96 4.86 7.12 8.85
Enterprise Value to EBITDA (EV/EBITDA)		 18.04 27.92 71.19 133.95 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 47.30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 67.57 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10.09
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -0.70 -0.66 -0.67 -0.66 -0.65 -0.67 -0.75 -0.77 -0.73 -0.79 -0.95
Long-Term Debt to Equity		 -0.70 -0.66 -0.67 -0.66 -0.65 -0.67 -0.75 -0.77 -0.73 -0.79 -0.95
Financial Leverage		 0.03 0.12 0.14 0.16 0.24 0.40 0.50 0.64 0.96 1.48 0.63
Leverage Ratio		 -1.02 -1.08 -1.15 -1.16 -1.22 -1.42 -1.65 -1.73 -2.11 -2.83 -2.12
Compound Leverage Factor		 -0.04 -6.24 2.02 1.65 -2.94 -2.11 -4.97 -6.23 -3.90 -4.37 -4.97
Debt to Total Capital		 -236.76% -195.49% -203.81% -193.98% -183.97% -199.11% -298.92% -333.18% -265.45% -367.81% -1,792.23%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 -236.76% -195.49% -203.81% -193.98% -183.97% -199.11% -298.92% -333.18% -265.45% -367.81% -1,792.23%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 336.76% 295.49% 303.81% 293.98% 283.97% 299.11% 398.92% 433.18% 365.45% 467.81% 1,892.23%
Debt to EBITDA		 3.65 5.74 14.57 33.60 -20.22 -11.44 -90.31 -27.04 -8.39 -4.65 -2.84
Net Debt to EBITDA		 0.02 -0.48 -1.66 -2.60 1.96 3.30 26.75 10.56 5.79 4.26 2.87
Long-Term Debt to EBITDA		 3.65 5.74 14.57 33.60 -20.22 -11.44 -90.31 -27.04 -8.39 -4.65 -2.84
Debt to NOPAT		 13.68 -176.88 -11.03 -7.43 -4.91 -4.18 -4.10 -3.78 -2.68 -2.23 -2.13
Net Debt to NOPAT		 0.08 14.89 1.26 0.58 0.48 1.21 1.21 1.48 1.85 2.04 2.16
Long-Term Debt to NOPAT		 13.68 -176.88 -11.03 -7.43 -4.91 -4.18 -4.10 -3.78 -2.68 -2.23 -2.13
Altman Z-Score		 -2.28 -2.56 -2.43 -2.85 -2.98 -2.62 -2.00 -1.92 -1.68 -1.07 -0.47
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.93 2.63 2.78 2.82 3.73 3.31 5.54 5.47 5.76 4.90 6.23
Quick Ratio		 2.78 2.49 2.62 2.64 3.31 2.97 4.97 5.01 5.25 4.50 5.75
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -55 -44 7.67 0.63 3.01 6.39 18 9.48 2.19 -14 305
Operating Cash Flow to CapEx		 -19,242.66% -772.30% 13,974.58% -882.58% -22,844.26% -1,609.75% -2,015.91% -4,028.69% -29,695.00% -4,534.03% -18,539.43%
Free Cash Flow to Firm to Interest Expense		 -2.34 -1.79 0.31 0.03 0.12 0.26 0.67 0.16 0.08 -0.54 12.31
Operating Cash Flow to Interest Expense		 -1.17 -0.21 0.33 -0.06 -2.19 -0.36 -0.73 -0.32 -1.73 -0.90 -1.31
Operating Cash Flow Less CapEx to Interest Expense		 -1.18 -0.24 0.33 -0.06 -2.20 -0.39 -0.76 -0.33 -1.74 -0.92 -1.32
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.06 0.89 0.81 0.76 0.73 0.62 0.59 0.59 0.56 0.48 0.58
Accounts Receivable Turnover		 6.54 6.63 6.54 6.05 6.51 6.16 6.60 6.18 6.81 6.77 6.93
Inventory Turnover		 0.85 0.67 0.42 0.36 0.17 0.16 0.19 0.31 0.33 0.30 0.22
Fixed Asset Turnover		 65.29 57.46 50.25 47.48 43.86 40.11 36.37 35.78 33.73 31.25 29.27
Accounts Payable Turnover		 1.42 0.75 0.64 0.52 0.53 0.25 0.55 0.60 0.71 0.30 0.31
Days Sales Outstanding (DSO)		 55.81 55.08 55.78 60.36 56.09 59.22 55.32 59.01 53.58 53.92 52.68
Days Inventory Outstanding (DIO)		 429.58 546.95 877.85 1,022.36 2,169.80 2,289.54 1,948.08 1,186.94 1,120.49 1,233.87 1,671.05
Days Payable Outstanding (DPO)		 257.35 483.98 567.63 703.86 688.46 1,435.60 659.88 610.13 517.34 1,200.83 1,163.06
Cash Conversion Cycle (CCC)		 228.04 118.04 366.00 378.86 1,537.43 913.16 1,343.51 635.83 656.74 86.95 560.66
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -450 -502 -504 -500 -506 -543 -502 -505 -493 -507 -475
Invested Capital Turnover		 -1.05 -0.86 -0.82 -0.76 -0.71 -0.63 -0.65 -0.62 -0.60 -0.54 -0.75
Increase / (Decrease) in Invested Capital		 56 41 -2.28 5.50 -13 -36 -27 -24 -22 -18 -317
Enterprise Value (EV)		 1,569 1,531 1,536 1,251 1,011 1,139 1,250 1,213 1,407 1,928 2,110
Market Capitalization		 1,567 1,558 1,572 1,275 1,040 1,227 1,342 1,330 1,572 2,140 2,343
Book Value per Share		 ($2.16) ($2.30) ($2.26) ($2.30) ($2.31) ($2.22) ($2.17) ($2.06) ($1.74) ($1.58) ($1.31)
Tangible Book Value per Share		 ($2.16) ($2.30) ($2.26) ($2.30) ($2.31) ($2.22) ($2.17) ($2.06) ($1.74) ($1.58) ($1.31)
Total Capital		 -134 -161 -154 -162 -168 -152 -103 -90 -90 -63 -13
Total Debt		 318 315 314 314 308 303 308 299 238 232 230
Total Long-Term Debt		 318 315 314 314 308 303 308 299 238 232 230
Net Debt		 1.80 -27 -36 -24 -30 -88 -91 -117 -165 -212 -233
Capital Expenditures (CapEx)		 0.14 0.68 0.06 0.16 0.24 0.55 0.99 0.47 0.16 0.53 0.18
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -25 -59 -57 -39 -11 -45 13 5.31 6.11 -15 -0.94
Debt-free Net Working Capital (DFNWC)		 270 262 274 234 327 346 412 418 406 411 427
Net Working Capital (NWC)		 270 262 274 234 327 346 412 418 406 411 427
Net Nonoperating Expense (NNE)		 0.86 24 19 19 25 32 28 61 33 39 30
Net Nonoperating Obligations (NNO)		 1.80 -27 -36 -24 -30 -88 -91 -117 -165 -212 -233
Total Depreciation and Amortization (D&A)		 13 12 13 16 17 16 20 21 19 43 18
Debt-free, Cash-free Net Working Capital to Revenue		 -5.02% -13.20% -13.88% -10.32% -3.14% -13.52% 3.95% 1.73% 2.11% -5.46% -0.39%
Debt-free Net Working Capital to Revenue		 53.65% 58.04% 66.30% 61.32% 92.06% 104.40% 129.65% 136.17% 140.06% 151.75% 179.23%
Net Working Capital to Revenue		 53.65% 58.04% 66.30% 61.32% 92.06% 104.40% 129.65% 136.17% 140.06% 151.75% 179.23%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.13) ($0.07) ($0.06) ($0.17) ($0.31) ($0.19) ($0.40) ($0.28) ($0.38) ($0.23)
Adjusted Weighted Average Basic Shares Outstanding		 208.88M 206.70M 206.91M 206.43M 206.06M 192.20M 189.64M 189.12M 188.51M 185.91M 186.18M
Adjusted Diluted Earnings per Share		 $0.00 ($0.13) ($0.07) ($0.06) ($0.17) ($0.31) ($0.19) ($0.40) ($0.28) ($0.38) ($0.23)
Adjusted Weighted Average Diluted Shares Outstanding		 215.26M 206.70M 206.91M 206.43M 206.06M 192.20M 189.64M 189.12M 188.51M 185.91M 186.18M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 209.25M 208.96M 207.13M 206.89M 206.38M 206.15M 204.81M 189.49M 188.93M 188.45M 186.42M
Normalized Net Operating Profit after Tax (NOPAT)		 15 -3.16 5.38 6.13 -10 -30 -8.34 -14 -20 -32 -12
Normalized NOPAT Margin		 10.21% -2.40% 4.60% 5.61% -10.93% -31.98% -9.62% -17.57% -28.92% -40.75% -16.10%
Pre Tax Income Margin		 0.52% -19.76% -11.48% -11.43% -37.75% -67.62% -41.29% -90.42% -76.57% -89.84% -54.07%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.90 -0.18 0.31 0.35 -0.59 -1.74 -0.44 -0.36 -1.04 -1.75 -0.70
NOPAT to Interest Expense		 0.04 -0.13 0.22 0.25 -0.41 -1.22 -0.31 -0.25 -0.73 -1.23 -0.49
EBIT Less CapEx to Interest Expense		 0.90 -0.21 0.31 0.35 -0.60 -1.76 -0.47 -0.37 -1.04 -1.77 -0.71
NOPAT Less CapEx to Interest Expense		 0.03 -0.16 0.21 0.24 -0.42 -1.24 -0.34 -0.26 -0.73 -1.25 -0.50
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About BioCryst Pharmaceuticals' Financials

When does BioCryst Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, BioCryst Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has BioCryst Pharmaceuticals' net income changed over the last 10 years?

BioCryst Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$88.88 million in 2024, rising from -$45.19 million in 2014. The previous period was -$226.54 million in 2023. See where experts think BioCryst Pharmaceuticals is headed by visiting BioCryst Pharmaceuticals' forecast page.

What is BioCryst Pharmaceuticals's operating income?
BioCryst Pharmaceuticals's total operating income in 2024 was -$2.54 million, based on the following breakdown:
  • Total Gross Profit: $438.44 million
  • Total Operating Expenses: $440.99 million
How has BioCryst Pharmaceuticals revenue changed over the last 10 years?

Over the last 10 years, BioCryst Pharmaceuticals' total revenue changed from $13.61 million in 2014 to $450.71 million in 2024, a change of 3,212.1%.

How much debt does BioCryst Pharmaceuticals have?

BioCryst Pharmaceuticals' total liabilities were at $966.35 million at the end of 2024, a 0.6% decrease from 2023, and a 1,478.0% increase since 2014.

How much cash does BioCryst Pharmaceuticals have?

In the past 10 years, BioCryst Pharmaceuticals' cash and equivalents has ranged from $22.10 million in 2016 to $504.39 million in 2021, and is currently $104.71 million as of their latest financial filing in 2024.

How has BioCryst Pharmaceuticals' book value per share changed over the last 10 years?

Over the last 10 years, BioCryst Pharmaceuticals' book value per share changed from 1.13 in 2014 to -2.30 in 2024, a change of -302.9%.


Related Companies

This page (NASDAQ:BCRX) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...
Colonial Metals | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
Trump’s Bitcoin Reserve is No Accident…
Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...
Crypto 101 Media | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
Massive new energy source found in Utah
NEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...
Stansberry Research | Sponsored